-
公开(公告)号：WO2022178243A1
公开(公告)日：2022-08-25
申请号：PCT/US2022/016961
申请日：2022-02-18
申请人： KITE PHARMA, INC.
发明人： BOT, Adrian , CHOU, Szu-Ting , PLAKS, Vicki , PODDAR, Soumya , ROSSI, John
IPC分类号： C12Q1/6886 , G01N33/574
摘要： The disclosure relates to methods of diagnosis and prognosis, compositions for immunotherapies, methods of improving said compositions, and immunotherapies using the same (e.g., T cells, non-T cells, TCR-based therapies, CAR-based therapies, bispecific T-cell engagers (BiTEs), and/or immune checkpoint blockade).
-
公开(公告)号：WO2019246563A1
公开(公告)日：2019-12-26
申请号：PCT/US2019/038547
申请日：2019-06-21
申请人： KITE PHARMA, INC.
发明人： EMTAGE, Peter , ROMAIN, Gabrielle , VINCENT, Rosa , WYMAN, Sarah
IPC分类号： C07K14/715 , C12N15/62 , C07K14/54
摘要： Provided herein are chimeric transmembrane proteins comprising a transmembrane domain of an alpha chain of interleukin-7 receptor with one or more modifications. Also provided herein are nucleic acids encoding these chimeric transmembrane proteins, and mammalian cells containing these nucleic acids, and methods of making and using these mammalian cells.
-
公开(公告)号：WO2019183389A1
公开(公告)日：2019-09-26
申请号：PCT/US2019/023424
申请日：2019-03-21
申请人： KITE PHARMA, INC.
发明人： EMTAGE, Peter , VINCENT, Rosa
IPC分类号： C07K14/55 , C07K14/715
摘要： Provided herein are chimeric transmembrane proteins, nucleic acids encoding these chimeric transmembrane proteins, and mammalian cells containing these nucleic acids, and methods of making and using these mammalian cells.
-
公开(公告)号：WO2019060695A1
公开(公告)日：2019-03-28
申请号：PCT/US2018/052184
申请日：2018-09-21
申请人： KITE PHARMA, INC.
IPC分类号： C07K16/28 , C07K14/705
摘要： The invention provides novel peptides ( e.g ., linkers) and polypeptide compositions comprising the linkers ( e.g ., fusion proteins) and methods of using the polypeptide compositions. Peptides ( e.g ., linkers) are useful as tags and for engineering fusion proteins ( e.g ., antigen binding molecules, scFv). Polypeptide linkers described herein facilitate flexibility of linked peptides allowing for proper folding, conformation and reduced immunogenicity.
-
公开(公告)号：WO2018200496A1
公开(公告)日：2018-11-01
申请号：PCT/US2018/029107
申请日：2018-04-24
申请人： KITE PHARMA, INC.
摘要： The invention provides a humanized anti-CD 19 antibody or antigen binding fragment thereof comprising a light chain variable (VL) region and a heavy chain variable (VH) region in which the humanized VL and VL regions are derived from the mouse anti-CD 19 clone FMC63 antibody; the humanized VL and/or humanized VH region comprise one or more amino acid substitutions in the framework region. The humanized anti-CD 19 antibody or antigen binding fragment may be part of a single chain variable fragment (scFv), a chimeric antigen receptor (CAR) or a T cell receptor (TCR). Other aspects of the invention relate to cells comprising the CAR or the TCR and their use in a T cell therapy.
-
6.发明申请
公开(公告)号：WO2018187332A1
公开(公告)日：2018-10-11
申请号：PCT/US2018/025888
申请日：2018-04-03
申请人： KITE PHARMA, INC.
发明人： ROSSI, John, M. , BOT, Adrian, I.
摘要： The disclosure provides methods of treating a malignancy comprising administering an effective dose of a chimeric receptor (e.g., CAR or TCR) genetically modified T cell immunotherapy. Some aspects of the disclosure relate to methods of determining an effective dose of a T cell immunotherapy comprising polyfunctional T cells prior to administration to the patient.
-
公开(公告)号：WO2018169922A3
公开(公告)日：2018-09-20
申请号：PCT/US2018/022126
申请日：2018-03-13
申请人： KITE PHARMA, INC.
IPC分类号： C07K14/435
摘要： The present invention relates to Chimeric Antigen Receptors (CARs) comprising antigen binding domains that specifically bind melanoma cells, polynucleotides encoding such CARs, and vectors comprising such polynucleotides. The present invention further relates to engineered cells comprising such polynucleotides and/or transduced with such viral vectors, and compositions including a plurality of engineered T cells. The present invention also relates to methods for manufacturing such engineered T cells and compositions and uses in treating a melanoma such engineered T cells and compositions.
-
公开(公告)号：WO2018013563A1
公开(公告)日：2018-01-18
申请号：PCT/US2017/041534
申请日：2017-07-11
申请人： KITE PHARMA, INC.
摘要： Isolated antigen binding molecules that specifically binds to a molecule comprising an amino acid sequence selected from the group consisting of GSTSGSGKPGSGEGSTKG (SEQ ID NO: 1), GSGKPGSGEG (SEQ ID NO: 2), GKPGSGEG (SEQ ID NO: 3), SGKPGSGE (SEQ ID NO: 499) and KPGSG (SEQ ID NO: 500) are provided. The antigen binding molecules can be used in the methods provided herein.
摘要翻译： 与包含选自GSTSGSGKPGSGEGSTKG（SEQ ID NO：1），GSGKPGSGEG（SEQ ID NO：2），GKPGSGEG（SEQ ID NO：1）和SEQ ID NO：2的氨基酸序列的分子特异性结合的分离的抗原结合分子， ID NO：3），SGKPGSGE（SEQ ID NO：499）和KPGSG（SEQ ID NO：500）。 抗原结合分子可用于本文提供的方法中。
-
公开(公告)号：WO2017173384A1
公开(公告)日：2017-10-05
申请号：PCT/US2017/025573
申请日：2017-03-31
申请人： KITE PHARMA, INC.
IPC分类号： A61K31/7068 , A61K35/17 , A61K38/17 , A61K39/00 , A61K39/395 , A61K45/06
摘要： Antigen binding molecules, chimeric receptors, and engineered immune cells are disclosed in accordance with the invention. The invention further relates to vectors, compositions, and methods of treatment and/or detection using the antigen binding molecules and engineered immune cells.
摘要翻译： 根据本发明公开了抗原结合分子，嵌合受体和工程化免疫细胞。 本发明还涉及使用抗原结合分子和工程化免疫细胞进行治疗和/或检测的载体，组合物和方法。
-
公开(公告)号：WO2017173256A1
公开(公告)日：2017-10-05
申请号：PCT/US2017/025351
申请日：2017-03-31
申请人： KITE PHARMA, INC.
发明人： WILTZIUS, Jed
IPC分类号： A61K48/00 , C07K14/705
摘要： The invention provides a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising extracellular domain disclosed herein. Some aspects of the invention relate to a polynucleotide encoding a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising the extracellular domain disclosed herein. Other aspects of the invention relate to cells comprising the CAR or the TCR and their use in a T cell therapy.
摘要翻译： 本发明提供了包含本文公开的细胞外结构域的嵌合抗原受体（CAR）或T细胞受体（TCR）。 本发明的一些方面涉及编码包含本文公开的细胞外结构域的嵌合抗原受体（CAR）或T细胞受体（TCR）的多核苷酸。 本发明的其他方面涉及包含CAR或TCR的细胞及其在T细胞疗法中的用途。
-
-
-
-
-
-
-
-
-
搜索结果
50 条记录 (耗时 0.034 秒)
